肥厚型梗阻性心肌病的药物治疗进展

www.yongyao.net　　2009-11-11 11:46:07　　来源：　　责任编辑：

分享到：

[ 参考文献]
[ 1 ] 　Sp irito P, Autore C. Management of hypertrophic cardiomyopathy [ J ]. BMJ ,2006, 332 (7552) : 1251-1255.
[ 2 ] 　Maron BJ ,McKennaWJ ,Danielson GK, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy [ J ]. Eur Heart J , 2003, 24 (21) : 1965-1991.
[ 3 ] 　Maron BJ. Hypertrophic cardiomyopathy: a systematic review [ J ]. JAMA, 2002,287 (10) : 1308-1320.
[ 4 ] 　Maron MS, Gohman TE, Casey SA, et al. Significance and relationship between magnitude of left ventricular hypertrophy and congestive heart failure symp tomsin hypertrophic cardiomyopathy [ J ]. J Am Coll Cardiol, 2002, 39 ( supp l A ) :173.
[ 5 ] 　Ostman2Smith I,Wettrell G, Riesenfeld T. A cohort study of childhood hypertrophic cardiomyopathy: imp roved survival following high2dose beta2adrenocep tor antagonist treatment [ J ]. J Am Coll Cardiol, 1999, 34 (6) : 1813-1822.
[ 6 ] 　Sp irito P, Seidman CE,McKennaMJ , et al. Themanagement of hypertrophic cardiomyopathy [ J ]. N Engl J Med, 1997, 336 (11) : 775-785.
[ 7 ] 　Borja J , Izquierdo J , Guindo J. Hypertrophic cardiomyopathy: combination ofβblockers and verapamilmay be risky [ J ]. BMJ , 2006, 333 (7558) : 97.
[ 8 ] 　中华医学会心血管病学分会,中华心血管病杂志编辑委员会,中国心肌病诊断与治疗建议工作组. 心肌病诊断与治疗建议[ J ]. 中华心血管病杂志,2007, 35 (1) : 5-16.
[ 9 ] 　FiferMA,O′Gara PT,McGovern BA, et al. Effects of disopyramide on left ventricular diastolic function in hypertrophic cardiomyopathy [ J ]. Am J Cardiol,1994, 74 (4) : 405.
[ 10 ] 　SherridMV,Barac I,McKennaWJ. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy [ J ]. J Am CollCardiol, 2005, 45 (8) : 1251-1258.
[ 11 ] 　HamadaM, Shigematsu Y, Inaba S, et al. Antiarrhythmic drug cibenzoline attenuates left ventricular p ressure gradient and imp roves transmitralDopp ler flow pattern in patientswith hypertrophic obstructive cardiomyopathy caused bymidventricular obstruction [ J ]. Circ J , 2005, 69 (8) : 940-945.
[ 12 ] 　Araujo AQ,Arteaga E, Ianni BM. Effect of losartan on left ventricular diastolic function in patientswith nonobstructive hypertrophic cardiomyopathy [ J ]. Am JCardiol, 2005, 96 (11) : 1563-1567.
[ 13 ] 　Kawano H, Toda G,Nakamizo R, et al. Valsartan decreases type I collagen synthesis in patientswith hypertrophic cardiomyopathy [ J ]. Circ J , 2005, 69 (10) :1244-1248.
[ 14 ] 　Tsybouleva N, Zhang L, Chen S, et al. A ldosterone, through novel signaling p roteins, is a fundamentalmolecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy [ J ]. Circulation, 2004, 109(10) : 1284-1291.
[ 15 ] 　Patel R,Nagueh SF, Tsybouleva N, et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and imp roves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy [ J ]. Circulation, 2001, 104(3) : 317-324.
[ 16 ] 　StaufferBL, Konhilas JP, Luczak ED, et al. Soy diet worsens heart disease inmice [ J ]. J Clin Invest, 2006, 116 (1) : 209-216.

来源：心血管病学进展作者：陶永康，李一石，樊朝美